AI assistant
Summit Therapeutics Inc. — Director's Dealing 2025
May 2, 2025
30436_dirs_2025-05-01_f58622dc-73d7-4528-909f-126f7de6531e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-04-29
Reporting Person: DUGGAN ROBERT W (Director, Co-Chief Executive Officer, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-29 | Stock Option (right to buy) | $1.06 | A | 1040000 | Acquired | 2032-06-28 | Common Stock (1040000) | Indirect |
| 2025-04-29 | Stock Option (right to buy) | $1.29 | A | 400000 | Acquired | 2032-09-09 | Common Stock (400000) | Indirect |
| 2025-04-29 | Stock Option (right to buy) | $1.68 | A | 9590558 | Acquired | 2033-10-13 | Common Stock (9590558) | Indirect |
Footnotes
F1: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025.
F2: Not applicable.
F3: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.